Abstract
Increasingly, government policies directed towards limiting pharmaceutical prices have emphasized value-based criteria. This regulatory approach is most clearly formalized in the United Kingdom where the National Institute for Health and Clinical Excellence (NICE) was created within the British National Health Service (NHS), whose function is to apply cost-effectiveness analysis to new drugs. In contrast to Britain, there is no formal regulatory mechanism assuring cost-effectiveness in the United States. Instead, questions of cost effectiveness are left to market processes. In this paper, we examine the pricing implications of these alternate regimes. From our empirical analysis, we conclude that value-based pricing is enforced by both regulatory and market processes, and with similar outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
